|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hernandez-Aya LF and Gonzalez-Angulo AM:
Adjuvant systemic therapies in breast cancer. Surg Clin North Am.
93:473–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Collignon J, Rorive A, Martin M, Andre C,
Maweja S, Lifrange E, Coucke P and Jerusalem G: Systemic
chemotherapy and breast cancer. Rev Med Liege. 66:372–378. 2011.(In
French). PubMed/NCBI
|
|
4
|
Saeki T, Tsuruo T, Sato W and Nishikawsa
K: Drug resistance in chemotherapy for breast cancer. Cancer
Chemother Pharmacol. 56(Suppl 1): 84–89. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coley HM: Mechanisms and strategies to
overcome chemotherapy resistance in metastatic breast cancer.
Cancer Treat Rev. 34:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roxanis I: Occurrence and significance of
epithelial-mesenchymal transition in breast cancer. J Clin Pathol.
66:517–521. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y and Zhou BP: Epithelial-mesenchymal
transition - a hallmark of breast cancer metastasis. Cancer Hallm.
1:38–49. 2013. View Article : Google Scholar
|
|
8
|
Dave B, Mittal V, Tan NM and Chang JC:
Epithelial-mesenchymal transition, cancer stem cells and treatment
resistance. Breast Cancer Res. 14:2022012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mallini P, Lennard T, Kirby J and Meeson
A: Epithelial-to-mesenchymal transition: What is the impact on
breast cancer stem cells and drug resistance. Cancer Treat Rev.
40:341–348. 2014. View Article : Google Scholar
|
|
10
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shah PD and Dickler MN: Endocrine therapy
for advanced breast cancer. Clin Adv Hematol Oncol. 12:214–223.
2014.PubMed/NCBI
|
|
14
|
Normanno N, Di Maio M, De Maio E, De Luca
A, de Matteis A, Giordano A and Perrone F; NCI-Naple Breast Cancer
Group. Mechanisms of endocrine resistance and novel therapeutic
strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
16
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al; Breast Cancer International Research Group. Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med.
365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin-Castillo B, Oliveras-Ferraros C,
Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B,
Urruticoechea A, Martín ÁG, López-Bonet E and Menendez JA:
Basal/HER2 breast carcinomas: Integrating molecular taxonomy with
cancer stem cell dynamics to predict primary resistance to
trastuzumab (Herceptin). Cell Cycle. 12:225–245. 2013. View Article : Google Scholar :
|
|
18
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foroni C, Broggini M, Generali D and Damia
G: Epithelial-mesenchymal transition and breast cancer: Role,
molecular mechanisms and clinical impact. Cancer Treat Rev.
38:689–697. 2012. View Article : Google Scholar
|
|
20
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Voulgari A and Pintzas A:
Epithelial-mesenchymal transition in cancer metastasis: Mechanisms,
markers and strategies to overcome drug resistance in the clinic.
Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
|
|
22
|
Bezdenezhnykh N, Semesiuk N, Lykhova O,
Zhylchuk V and Kudryavets Y: Impact of stromal cell components of
tumor microenvironment on epithelial-mesenchymal transition in
breast cancer cells. Exp Oncol. 36:72–78. 2014.PubMed/NCBI
|
|
23
|
Bonde AK, Tischler V, Kumar S, Soltermann
A and Schwendener RA: Intratumoral macrophages contribute to
epithelial-mesenchymal transition in solid tumors. BMC Cancer.
12:352012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Orimo A, Gupta PB, Sgroi DC,
Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL
and Weinberg RA: Stromal fibroblasts present in invasive human
breast carcinomas promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vega S, Morales AV, Ocaña OH, Valdés F,
Fabregat I and Nieto MA: Snail blocks the cell cycle and confers
resistance to cell death. Genes Dev. 18:1131–1143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kajita M, McClinic KN and Wade PA:
Aberrant expression of the transcription factors snail and slug
alters the response to genotoxic stress. Mol Cell Biol.
24:7559–7566. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen WJ, Wang H, Tang Y, Liu CL, Li HL and
Li WT: Multidrug resistance in breast cancer cells during
epithelial-mesenchymal transition is modulated by breast cancer
resistant protein. Chin J Cancer. 29:151–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li W, Liu C, Tang Y, Li H, Zhou F and Lv
S: Overexpression of Snail accelerates adriamycin induction of
multidrug resistance in breast cancer cells. Asian Pac J Cancer
Prev. 12:2575–2580. 2011.
|
|
31
|
Prasad CP, Rath G, Mathur S, Bhatnagar D,
Parshad R and Ralhan R: Expression analysis of E-cadherin, Slug and
GSK3beta in invasive ductal carcinoma of breast. BMC Cancer.
9:3252009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iseri OD, Kars MD, Arpaci F, Atalay C, Pak
I and Gunduz U: Drug resistant MCF-7 cells exhibit
epithelial-mesenchymal transition gene expression pattern. Biomed
Pharmacother. 65:40–45. 2011. View Article : Google Scholar
|
|
33
|
Luqmani YA, Al Azmi A, Al Bader M, Abraham
G and El Zawahri M: Modification of gene expression induced by
siRNA targeting of estrogen receptor alpha in MCF7 human breast
cancer cells. Int J Oncol. 34:231–242. 2009.
|
|
34
|
Andreeva OE, Shcherbakov AM, Shatskaia VA
and Krasilńikov MA: The role of transcription factor Snail1 in the
regulation of hormonal sensitivity of in vitro cultured breast
cancer cells. Vopr Onkol. 58:71–76. 2012.(In Russian).
|
|
35
|
Dhasarathy A, Kajita M and Wade PA: The
transcription factor snail mediates epithelial to mesenchymal
transitions by repression of estrogen receptor-alpha. Mol
Endocrinol. 21:2907–2918. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX
and Barsky SH: ERalpha suppresses slug expression directly by
transcriptional repression. Biochem J. 416:179–187. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bandyopadhyay A, Wang L, Agyin J, Tang Y,
Lin S, Yeh IT, De K and Sun LZ: Doxorubicin in combination with a
small TGFbeta inhibitor: A potential novel therapy for metastatic
breast cancer in mouse models. PLoS One. 5:e103652010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hirohashi S and Kanai Y: Cell adhesion
system and human cancer morphogenesis. Cancer Sci. 94:575–581.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
López-Díaz FJ, Gascard P, Balakrishnan SK,
Zhao J, Del Rincon SV, Spruck C, Tlsty TD and Emerson BM:
Coordinate transcriptional and translational repression of p53 by
TGF-β1 impairs the stress response. Mol Cell. 50:552–564. 2013.
View Article : Google Scholar
|
|
43
|
Shi XP, Miao S, Wu Y, Zhang W, Zhang XF,
Ma HZ, Xin HL, Feng J, Wen AD and Li Y: Resveratrol sensitizes
tamoxifen in antiestrogen-resistant breast cancer cells with
epithelial-mesenchymal transition features. Int J Mol Sci.
14:15655–15668. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang SE, Xiang B, Guix M, Olivares MG,
Parker J, Chung CH, Pandiella A and Arteaga CL: Transforming growth
factor beta engages TACE and ErbB3 to activate
phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast
cancer and desensitizes cells to trastuzumab. Mol Cell Biol.
28:5605–5620. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Walsh LA and Damjanovski S: IGF-1
increases invasive potential of MCF-7 breast cancer cells and
induces activation of latent TGF-β1 resulting in epithelial to
mesenchymal transition. Cell Commun Signal. 9:102011. View Article : Google Scholar
|
|
46
|
Gooch JL, Van Den Berg CL and Yee D:
Insulin-like growth factor (IGF)-I rescues breast cancer cells from
chemotherapy-induced cell death - proliferative and anti-apoptotic
effects. Breast Cancer Res Treat. 56:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nahta R, Yuan LX, Zhang B, Kobayashi R and
Esteva FJ: Insulin-like growth factor-I receptor/human epidermal
growth factor receptor 2 heterodimerization contributes to
trastuzumab resistance of breast cancer cells. Cancer Res.
65:11118–11128. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gan Y, Wientjes MG and Au JL: Expression
of basic fibroblast growth factor correlates with resistance to
paclitaxel in human patient tumors. Pharm Res. 23:1324–1331. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
McLeskey SW, Zhang L, El-Ashry D, Trock
BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson
RB, et al: Tamoxifen-resistant fibroblast growth factor-transfected
MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI
182,780 and two aromatase inhibitors. Clin Cancer Res. 4:697–711.
1998.PubMed/NCBI
|
|
50
|
Magnani L, Stoeck A, Zhang X, Lánczky A,
Mirabella AC, Wang TL, Gyorffy B and Lupien M: Genome-wide
reprogramming of the chromatin landscape underlies endocrine
therapy resistance in breast cancer. Proc Natl Acad Sci USA.
110:E1490–E1499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang CC, Yan Z, Zong Q, Fang DD, Painter
C, Zhang Q, Chen E, Lira ME, John-Baptiste A and Christensen JG:
Synergistic effect of the γ-secretase inhibitor PF-03084014 and
docetaxel in breast cancer models. Stem Cells Transl Med.
2:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pandya K, Meeke K, Clementz AG, Rogowski
A, Roberts J, Miele L, Albain KS and Osipo C: Targeting both Notch
and ErbB-2 signalling pathways is required for prevention of
ErbB-2-positive breast tumour recurrence. Br J Cancer. 105:796–806.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Orlowski RZ and Baldwin AS Jr: NF-kappaB
as a therapeutic target in cancer. Trends Mol Med. 8:385–389. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tapia MA, González-Navarrete I, Dalmases
A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J,
Mezquita C, Bachs O, et al: Inhibition of the canonical IKK/NF
kappa B pathway sensitizes human cancer cells to doxorubicin. Cell
Cycle. 6:2284–2292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Musgrove EA and Sutherland RL: Biological
determinants of endocrine resistance in breast cancer. Nat Rev
Cancer. 9:631–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gee JM, Robertson JF, Ellis IO and
Nicholson RI: Phosphorylation of ERK1/2 mitogen-activated protein
kinase is associated with poor response to anti-hormonal therapy
and decreased patient survival in clinical breast cancer. Int J
Cancer. 95:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Loh YN, Hedditch EL, Baker LA, Jary E,
Ward RL and Ford CE: The Wnt signalling pathway is upregulated in
an in vitro model of acquired tamoxifen resistant breast cancer.
BMC Cancer. 13:1742013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wu Y, Ginther C, Kim J, Mosher N, Chung S,
Slamon D and Vadgama JV: Expression of Wnt3 activates Wnt/β-catenin
pathway and promotes EMT-like phenotype in trastuzumab-resistant
HER2-overexpressing breast cancer cells. Mol Cancer Res.
10:1597–1606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kumar A, Xu J, Brady S, Gao H, Yu D,
Reuben J and Mehta K: Tissue transglutaminase promotes drug
resistance and invasion by inducing mesenchymal transition in
mammary epithelial cells. PLoS One. 5:e133902010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Liu Y, Du F, Chen W, Yao M, Lv K and Fu P:
Knockdown of dual specificity phosphatase 4 enhances the
chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to
doxorubicin. Exp Cell Res. 319:3140–3149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim MR, Choi HK, Cho KB, Kim HS and Kang
KW: Involvement of Pin1 induction in epithelial-mesenchymal
transition of tamoxifen-resistant breast cancer cells. Cancer Sci.
100:1834–1841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Asiedu MK, Beauchamp-Perez FD, Ingle JN,
Behrens MD, Radisky DC and Knutson KL: AXL induces
epithelial-to-mesenchymal transition and regulates the function of
breast cancer stem cells. Oncogene. 33:1316–1324. 2014. View Article : Google Scholar :
|
|
64
|
Dontu G, Abdallah WM, Foley JM, Jackson
KW, Clarke MF, Kawamura MJ and Wicha MS: In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells.
Genes Dev. 17:1253–1270. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: The cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jordan CT, Guzman ML and Noble M: Cancer
stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kakarala M and Wicha MS: Implications of
the cancer stem-cell hypothesis for breast cancer prevention and
therapy. J Clin Oncol. 26:2813–2820. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Morel AP, Lièvre M, Thomas C, Hinkal G,
Ansieau S and Puisieux A: Generation of breast cancer stem cells
through epithelial-mesenchymal transition. PLoS One. 3:e28882008.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Radisky DC and LaBarge MA:
Epithelial-mesenchymal transition and the stem cell phenotype. Cell
Stem Cell. 2:511–512. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells. Cancer Res.
69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: New insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Taube JH, Herschkowitz JI, Komurov K, Zhou
AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, et
al: Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and
metaplastic breast cancer subtypes. Proc Natl Acad Sci USA.
107:15449–15454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wielenga VJ, Smits R, Korinek V, Smit L,
Kielman M, Fodde R, Clevers H and Pals ST: Expression of CD44 in
Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J
Pathol. 154:515–523. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Vesuna F, Lisok A, Kimble B and Raman V:
Twist modulates breast cancer stem cells by transcriptional
regulation of CD24 expression. Neoplasia. 11:1318–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li J and Zhou BP: Activation of β-catenin
and Akt pathways by Twist are critical for the maintenance of EMT
associated cancer stem cell-like characters. BMC Cancer. 11:492011.
View Article : Google Scholar
|
|
78
|
Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang
Z, Yang CJ, Yuan L and Ouyang G: Twist2 contributes to breast
cancer progression by promoting an epithelial-mesenchymal
transition and cancer stem-like cell self-renewal. Oncogene.
30:4707–4720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Guo W, Keckesova Z, Donaher JL, Shibue T,
Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell
G, et al: Slug and Sox9 cooperatively determine the mammary stem
cell state. Cell. 148:1015–1028. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pályi-Krekk Z, Barok M, Isola J, Tammi M,
Szöllosi J and Nagy P: Hyaluronan-induced masking of ErbB2 and
CD44-enhanced trastuzumab internalisation in trastuzumab resistant
breast cancer. Eur J Cancer. 43:2423–2433. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Lesniak D, Sabri S, Xu Y, Graham K,
Bhatnagar P, Suresh M and Abdulkarim B: Spontaneous
epithelial-mesenchymal transition and resistance to HER-2-targeted
therapies in HER-2-positive luminal breast cancer. PLoS One.
8:e719872013. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Oliveras-Ferraros C, Corominas-Faja B,
Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM,
López-Bonet E, Martin ÁG and Menendez JA: Epithelial-to-mesenchymal
transition (EMT) confers primary resistance to trastuzumab
(Herceptin). Cell Cycle. 11:4020–4032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Lamouille S, Subramanyam D, Blelloch R and
Derynck R: Regulation of epithelial-mesenchymal and
mesenchymal-epithelial transitions by microRNAs. Curr Opin Cell
Biol. 25:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Adam L, Zhong M, Choi W, Qi W, Nicoloso M,
Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al:
miR-200 expression regulates epithelial-to-mesenchymal transition
in bladder cancer cells and reverses resistance to epidermal growth
factor receptor therapy. Clin Cancer Res. 15:5060–5072. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bojmar L, Karlsson E, Ellegård S, Olsson
H, Björnsson B, Hallböök O, Larsson M, Stål O and Sandström P: The
role of microRNA-200 in progression of human colorectal and breast
cancer. PLoS One. 8:e848152013. View Article : Google Scholar :
|
|
89
|
Cochrane DR, Spoelstra NS, Howe EN,
Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and
restores sensitivity to microtubule-targeting chemotherapeutic
agents. Mol Cancer Ther. 8:1055–1066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chen Y, Sun Y, Chen L, Xu X, Zhang X, Wang
B, Min L and Liu W: miRNA-200c increases the sensitivity of breast
cancer cells to doxorubicin through the suppression of
E-cadherin-mediated PTEN/Akt signaling. Mol Med Rep. 7:1579–1584.
2013.PubMed/NCBI
|
|
91
|
Manavalan TT, Teng Y, Litchfield LM,
Muluhngwi P, Al-Rayyan N and Klinge CM: Reduced expression of
miR-200 family members contributes to antiestrogen resistance in
LY2 human breast cancer cells. PLoS One. 8:e623342013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Liu Z, Liu H, Desai S, Schmitt DC, Zhou M,
Khong HT, Klos KS, McClellan S, Fodstad O and Tan M: miR-125b
functions as a key mediator for snail-induced stem cell propagation
and chemoresistance. J Biol Chem. 288:4334–4345. 2013. View Article : Google Scholar :
|
|
93
|
Wang HJ, Guo YQ, Tan G, Dong L, Cheng L,
Li KJ, Wang ZY and Luo HF: miR-125b regulates side population in
breast cancer and confers a chemoresistant phenotype. J Cell
Biochem. 114:2248–2257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Guttilla IK, Phoenix KN, Hong X, Tirnauer
JS, Claffey KP and White BA: Prolonged mammosphere culture of MCF-7
cells induces an EMT and repression of the estrogen receptor by
microRNAs. Breast Cancer Res Treat. 132:75–85. 2012. View Article : Google Scholar
|
|
95
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar
|
|
96
|
Liu T, Zhang X, Shang M, Zhang Y, Xia B,
Niu M, Liu Y and Pang D: Dysregulated expression of Slug, vimentin,
and E-cadherin correlates with poor clinical outcome in patients
with basal-like breast cancer. J Surg Oncol. 107:188–194. 2013.
View Article : Google Scholar
|
|
97
|
Soini Y, Tuhkanen H, Sironen R, Virtanen
I, Kataja V, Auvinen P, Mannermaa A and Kosma VM: Transcription
factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer.
11:732011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jeong H, Ryu YJ, An J, Lee Y and Kim A:
Epithelial-mesenchymal transition in breast cancer correlates with
high histological grade and triple-negative phenotype.
Histopathology. 60B:E87–E95. 2012. View Article : Google Scholar
|
|
99
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Baritaki S, Chapman A, Yeung K, Spandidos
DA, Palladino M and Bonavida B: Inhibition of epithelial to
mesenchymal transition in metastatic prostate cancer cells by the
novel proteasome inhibitor, NPI-0052: Pivotal roles of Snail
repression and RKIP induction. Oncogene. 28:3573–3585. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Shinto O, Yashiro M, Kawajiri H, Shimizu
K, Shimizu T, Miwa A and Hirakawa K: Inhibitory effect of a TGFbeta
receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous
gastric cancer cells. Br J Cancer. 102:844–851. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li L-N, Zhang H-D, Yuan S-J, Yang D-X,
Wang L and Sun Z-X: Differential sensitivity of colorectal cancer
cell lines to artesunate is associated with expression of
beta-catenin and E-cadherin. Eur J Pharmacol. 588:1–8. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Sokol JP, Neil JR, Schiemann BJ and
Schiemann WP: The use of cystatin C to inhibit
epithelial-mesenchymal transition and morphological transformation
stimulated by transforming growth factor-beta. Breast Cancer Res.
7:R844–R853. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Finn RS, Dering J, Ginther C, Wilson CA,
Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active
small molecule inhibitor of both the src and abl kinases,
selectively inhibits growth of basal-type/‘triple-negative' breast
cancer cell lines growing in vitro. Breast Cancer Res Treat.
105:319–326. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chua KN, Sim WJ, Racine V, Lee SY, Goh BC
and Thiery JP: A cell-based small molecule screening method for
identifying inhibitors of epithelial-mesenchymal transition in
carcinoma. PLoS One. 7:e331832012. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lu L, Zhou D, Jiang X, Song K, Li K and
Ding W: Loss of E-cadherin in multidrug resistant breast cancer
cell line MCF-7/Adr: Possible implication in the enhanced invasive
ability. Eur Rev Med Pharmacol Sci. 16:1271–1279. 2012.PubMed/NCBI
|
|
107
|
Roger L, Jullien L, Gire V and Roux P:
Gain of oncogenic function of p53 mutants regulates E-cadherin
expression uncoupled from cell invasion in colon cancer cells. J
Cell Sci. 123:1295–1305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zhang B, Groffen J and Heisterkamp N:
Increased resistance to a farnesyltransferase inhibitor by
N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells.
Leukemia. 21:1189–1197. 2007. View Article : Google Scholar : PubMed/NCBI
|
